The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles

Received for publication, May 17, 2017, and June 21, 2017 Published, Papers in Press, June 28, 2017, DOI 10.1074/jbc.M117.797332

Birthe Trautz, Hannah Wiedemann, Christian Lüchtenborg, Virginia Pierini, Jan Kranich, Bärbel Glass, Hans-Georg Kräusslich, Thomas Brocker, Massimo Pizzato, Alessia Ruggieri, Britta Brügge, and Oliver T. Fackler

From the Department of Infectious Diseases, Integrative Virology, and Department of Infectious Diseases, Virology, University Hospital Heidelberg, INF 324, 69120 Heidelberg, Germany, the Heidelberg University Biochemistry Center, INF 328, 69120 Heidelberg, Germany, the Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, INF 345, 69120 Heidelberg, Germany, the University of Trento, Centre for Integrative Biology, 38122 Trento, Italy, and the Institute for Immunology, Ludwig-Maximilians-Universität München, Großhaderner Straße 9, 82152 Planegg-Martinsried, Germany

Edited by Charles E. Samuel

The host-cell restriction factor SERINC5 potently suppresses the infectivity of HIV, type 1 (HIV-1) particles, and is counteracted by the viral pathogenesis factor Nef. However, the molecular mechanism by which SERINC5 restricts HIV-1 particle infectivity is still unclear. Because SERINC proteins have been suggested to facilitate the incorporation of serine during the biosynthesis of membrane lipids and because lipid composition of HIV particles is a major determinant of the infectious potential of the particles, we tested whether SERINC5-mediated restriction of HIV particle infectivity involves alterations of membrane lipid composition. We produced and purified HIV-1 particles from SERINC593T cells with very low endogenous SERINC5 levels under conditions in which ectopically expressed SERINC5 restricts HIV-1 infectivity and is antagonized by Nef and analyzed both virions and producer cells with quantitative lipid MS. SERINC5 restriction and Nef antagonism were not associated with significant alterations in steady-state lipid composition of producer cells and HIV particles. Sphingolipid metabolism kinetics were also unaltered by SERINC5 expression. Moreover, the levels of phosphatidylserine on the surface of HIV-1 particles, which may trigger uptake into non-productive internalization pathways in target cells, did not change upon expression of SERINC5 or Nef. Finally, saturating the phosphatidylserine-binding sites on HIV target cells did not affect SERINC5 restriction or Nef antagonism. These results demonstrate that the restriction of HIV-1 particle infectivity by SERINC5 does not depend on alterations in lipid composition and organization of HIV-1 particles and suggest that channeling serine into lipid biosynthesis may not be a cardinal cellular function of SERINC5.

For efficient replication in natural target cells, HIV has to surmount numerous physical barriers posed by cell-intrinsic restriction factors such as Trim5α, APOBEC3G, CD317/tetherin, Mx2, or SAMHD1 (1, 2). Because their expression is often triggered or enhanced by interferons, restriction factors are considered an essential arm of cell-intrinsic innate immunity. HIV can overcome these barriers by genetic adaptation, preventing the recognition of subviral structures by restriction factors (e.g. modification of HIV-1 capsid to prevent interaction with human Trim5α) or by expression of viral antagonists that counteract the antiviral activity of restriction factors. With Vif, Vpr, Vpu, and Nef, HIV-1 encodes four accessory proteins that are not essential for virus replication in cell culture but whose role in antagonizing host-cell restrictions to optimize virus spread in vivo is increasingly emerging. Although prominent restrictions antagonized by e.g. Vif (apolipoprotein B mRNA editing enzyme), Vpr (SLX4), and Vpu (CD317/tetherin) are well established (3–6), it was only recently that serine incorpo- rator 3 (SERINC3) and SERINC5 were identified as host cell restriction factors that potently impair the infectivity of HIV-1 virions and that are antagonized by HIV-1 Nef (7, 8).

Nef is a myristoylated, 25- to 34-kDa protein that, in addition to HIV-1, is encoded by HIV-2 and simian immunodeficiency virus. In the infected host, Nef potently increases virus replication and thus serves as a pathogenicity factor that accelerates disease progression (9–11). Nef affects many central processes in HIV target cells that may contribute to its role in AIDS pathogenesis, including down-regulation of an array of receptors from the surface of infected cells (12, 13), alteration of signal transduction pathways such as T cell receptor signaling.

This work was supported by Deutsche Forschungsgemeinschaft TRR83 Projects 1 (to B. B.), 14 (to H. G. K.), and 15 (to O. T. F.); SFB1129 Project 10 (to B. B.); as well as Projects RU 1950/1-1 (to A. R.), FA 378/17-1 (to O. T. F.), and KR 906/8-1 (to H. G. K.). The authors declare that they have no conflicts of interest. This article contains supplemental Table S1. Members of the cluster of excellence CellNetworks (EXC81), 1 To whom correspondence may be addressed. Tel.: 49-6221-545326; Fax: 49-6221-544486; E-mail: britta.bruegger@bzh.uni-heidelberg.de. 2 To whom correspondence may be addressed. Tel.: 49-6221-545326; Fax: 49-6221-544486; E-mail: oliver.fackler@med.uni-heidelberg.de. 3 The abbreviations used are: HIV-1, HIV, type 1; SM, sphingomyelin; HexCer, heksosyleramide; SP, sphingolipid(s); SERINC, serine incorporator; PS, phosphatidylserine; GP, glycerophospholipid(s); PE, phosphatidylethanolamine; GL, glycerolipid(s); HCV, hepatitis C virus; PE, phosphatidylethanolamine; APC, allophycocyanin; TFR, transferrin receptor; GP, phosphatidylglycerol; PI, phosphatidylinositol; ST, sterol(s); pacSph, photoactivatable and clickable analog of sphingosine; Nef, negative factor; HPTLC, high performance thin layer chromatography; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocho- line; DOPS, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.

This work was supported by Deutsche Forschungsgemeinschaft TRR83 Projects 1 (to B. B.), 14 (to H. G. K.), and 15 (to O. T. F.); SFB1129 Project 10 (to B. B.); as well as Projects RU 1950/1-1 (to A. R.), FA 378/17-1 (to O. T. F.), and KR 906/8-1 (to H. G. K.). The authors declare that they have no conflicts of interest. This article contains supplemental Table S1.

1 To whom correspondence may be addressed. Tel.: 49-6221-545326; Fax: 49-6221-544486; E-mail: bridget.brueger@bzh.uni-heidelberg.de.

2 To whom correspondence may be addressed. Tel.: 49-6221-545326; Fax: 49-6221-544486; E-mail: oliver.fackler@med.uni-heidelberg.de.

3 The abbreviations used are: HIV-1, HIV, type 1; SM, sphingomyelin; HexCer, heksosyleramide; SP, sphingolipid(s); SERINC, serine incorporator; PS, phosphatidylserine; GP, glycerophospholipid(s); PC, phosphatidylcholine; GL, glycerolipid(s); HCV, hepatitis C virus; PE, phosphatidylethanolamine; APC, allophycocyanin; TFR, transferrin receptor; GP, phosphatidylglycerol; PI, phosphatidylinositol; ST, sterol(s); pacSph, photoactivatable and clickable analog of sphingosine; Nef, negative factor; HPTLC, high performance thin layer chromatography; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPS, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.
(14–20), as well as interference with host-cell actin dynamics and motility (21–28). Nef also increases the infectivity of HIV-1 particles when expressed from proviral DNA in virus-producing cells (29–31). Although this effect is mild in most cell types, production of HIV-1 variants lacking Nef expression (HIV-1ΔNef) results in particles that are up to 100-fold less infectious than WT HIV-1 (32). These strong differences in virion infectivity correlate with high levels of SERINC5 expression, and Nef antagonizes the antiviral activity of SERINC5 under these conditions to restore full HIV-1 infectivity (7, 8). The mechanisms by which Nef antagonizes SERINC5 restriction to HIV infectivity are not fully understood (33). Nef expression reduces cell surface exposure and virion incorporation of SERINC5; however, these effects are not sufficient to fully account for the antagonism, suggesting that Nef can also inactivate virion-incorporated SERINC5 molecules (7, 8, 34).

Although some insight has emerged regarding the mechanism of SERINC5 antagonism by Nef, molecular details about how SERINC5 interferes with HIV infectivity remain elusive. SERINC5 is a member of the SERINC protein family that is conserved from yeast to mammals and encompasses five members that are predicted to contain 10–12 transmembrane domains (35, 36). SERINC5 is efficiently incorporated into HIV particles, and its presence in the virion may be critical for its antiviral activity (7, 8). In support of this model, SERINC5 reduces the efficacy of virus entry at the fusion step, and the Env glycoprotein contains a major determinant of HIV particles for sensitivity to SERINC5 restriction (7, 8, 37). A recent study suggested that the reduced fusogenicity of SERINC5-containing virions reflects a direct inactivation mechanism of the Env glycoprotein by the restriction factor (38), but the underlying molecular mechanism is still unclear. The overall biochemical properties and physiological roles of SERINC5 proteins are also not well characterized. The only report available to date describes that SERINC5 proteins, when ectopically expressed in Escherichia coli, yeast, and COS-7 cells, associate with key enzymes required for lipid and sphingolipid biosynthesis and incorporate serine into membranes, which coined the name serine incorporator (35). Reflecting that HIV buds from specialized plasma membrane microdomains, its lipid envelope displays a highly specialized lipid composition that is enriched in cholesterol and sphingolipids and that significantly differs from that of bulk plasma membrane (39, 40). This specialized lipid composition is critical for virion infectivity because, e.g., alterations thereof caused by inhibition of sphingolipid biosynthesis significantly reduce the infectivity of HIV-1 particles (39). Considering that serine is an essential building block of sphingolipid biosynthesis and that this process is critical for full infectivity of HIV-1 particles (39), we hypothesized that the antiviral activity of SERINC5 may be linked to modulation of host-cell lipid biosynthesis and/or lipid composition of virus particles. We noted previously that HIV-1 Nef has the ability to slightly modify the lipid and sphingolipid content of HIV-1 particles when produced from the human CD4 T cell line MT-4, which expresses little or no SERINC5 (7, 41), raising the possibility that this activity is emphasized in the presence of SERINC5 and allows Nef to antagonize the restriction. To test these hypotheses, we set out to define the impact of SERINC5 on HIV-1 particle lipid composition, lipid composition and sphingosine metabolism of HIV-producing cells, and lipid organization of HIV-1 virions.

Results

Purification of HIV particles produced in the presence of SERINC5

Ectopic expression of SERINC5 in 293T cells, which express low levels of endogenous SERINC5 that are not sufficient to exert significant antiviral activity (7), potently suppresses the infectivity of nef-negative HIV-1 (ΔNef), whereas Nef expression by WT HIV-1 antagonizes particle infectivity restriction by SERINC5 (7, 8, 34, 42). We therefore used ectopic expression of SERINC5 in 293T cells to test whether the presence of SERINC5 during the production of HIV particles affects the lipid composition of viral progeny. 293T cells were transfected with proviral plasmids together with an empty control or a SERINC5 expression plasmid (Fig. 1) in a large-scale format. Quantification of reverse transcriptase activity in the cell culture supernatants revealed that comparable amounts of virus particles were produced under all conditions (Fig. 1A). SERINC5 markedly reduced the relative infectivity of HIV-1 ΔNef particles, whereas expression of Nef from HIV-1 WT counteracted the antiviral activity of SERINC5 (Fig. 1B). Virus particles were purified from these cell culture supernatants via velocity gradient centrifugation using a protocol that yields HIV particles without substantial contamination with extracellular vesicles (39, 41). These concentrated virus preparations contained significant amounts of SERINC5 in the case of HIV-1 ΔNef, whereas only very low levels of the restriction factor were detectable in preparations of HIV-1 WT (Fig. 1C). SDS-PAGE and silver staining of these virus preparations confirmed that HIV-1 p24 was the main protein component of these preparations, which displayed comparable purity (Fig. 1D).

SERINC5 does not alter the lipid composition of HIV-producing cells or HIV particles

We next analyzed these HIV particle preparations and the corresponding producer cells by quantitative lipid mass spectrometry. To this end, we subjected purified viral particles and whole producer cells to lipid extractions in the presence of internal lipid standards. Lipid profiles of HIV-1 particles (Fig. 2A, primary data in supplemental Table S1) and producer cells (Fig. 2B) were determined by a bottom-up lipidomics approach based on precursor ion and neutral loss scanning for lipid class–specific fragments (43). In line with previous reports (39, 40, 44–47), HIV-1 WT particles were enriched in cholesterol, sphingomyelin (SM), hexosylceramide (HexCer), and phosphatidylserine (PS) compared with the producing cells (Fig. 2, A and B). No significant differences in lipid composition were observed between HIV-1 WT and ΔNef virions (Fig. 2A, major and rare lipid classes are shown in the left and right panel, respectively; compare light blue and dark blue columns). Presumably reflecting differences in the overall lipid composition of the cell lines used, these particles, produced from 293T cells, did not display the Nef-mediated enrichment in SM observed previously in virions produced from MT-4 cells (40, 41). Considering the suggested potential of SERINC proteins to feed
serine into sphingolipid (SP) biosynthesis, we expected that expression of SERINC5 during virus production may affect levels of host-cell and/or virion lipids that require serine during biosynthesis, such as SM, HexCer, and PS. However, and irrespective of the presence of Nef, expression of SERINC5 during virus production had no significant impact on the abundance of individual lipid classes in virions (Fig. 2A) or producer cells (Fig. 2B). Likewise, the overall category profile, including glycerophospholipids (GP), SP, and sterols (ST), was indistinguishable in virus producer cells and virions under all conditions tested (Fig. 2C).

Although overall lipid class profiles remained unchanged by the presence or absence of SERINC5 during virus production, differences might occur for individual lipid species within lipid classes. To test for changes at the level of molecular lipid species compositions, we first compared their distributions on a global level. In agreement with previous reports (39, 40, 44–47), we showed previously that dihydrosphingomyelin (annotated as SM 34:0;2 in Fig. 3A) was at the expense of species with a length of 34 and 36 carbons (e.g. PC 34:1, 36:2; O-34:1; O-36:2). Again, these profiles remained unchanged by the presence of Nef and/or SERINC5.

In turn, the overall length distribution of GP and SP species was overall similar in producer cells and virions under all conditions tested. As the only exception, GP-34 was slightly more abundant in cells than in virions (Fig. 3B).

Another profound difference between HIV-1 particles and membrane lipids of producer cells is the enrichment of saturated lipid species, contributing to the higher lateral order of particles (39, 40, 48). Accordingly, HIV-1 particles (WT as well as ΔNef) were enriched in GP with saturated fatty acyl moieties (Fig. 3C, left panel, e.g. GP-0), whereas only slight differences between producer cells and HIV particles were observed for the saturation of SP (Fig. 3C, right panel). For both lipid categories, absence of Nef and presence of SERINC5 did not impact the global GP and SP compositions. Thus, SERINC5 did not influence the partitioning of saturated lipid species or individual lipid classes into the viral membrane envelope.

A striking feature of HIV-1 and some other viruses is the enrichment of dihydrophingomyelin, such as N-palmitoyl-dihydrophingomyelin (annotated as SM 34:0;2 in Fig. 3A, right panel) in viral particles compared with producer cell lines (39, 40, 48, 49). We showed previously that dihydrophingomyelin is not enriched in HIV-1 particles produced from HEK293T cells (47). Consistently, we did not observe an increase in dihy-
dosphingomyelin, neither in HIV-1 WT nor in ΔNef particles produced in the absence or presence of SERINC5 (Fig. 3A, right panel, compare light blue and dark blue columns of the 34:0:2 species).

Taken together, expression of SERINC5 did not significantly alter the lipid composition of HIV-1-producing cells or the resulting virus particles. We conclude that, in the experimental system used, restriction of HIV particle infectivity by SERINC5

Figure 2. Quantitative lipid analysis of HIV-1–producing cells and purified HIV-1 particles. A and B, lipid composition of OptiPrep-purified HIV-1NL4.3 WT or ΔNef particles produced in the absence or presence of SERINC5 (A) and of the corresponding 293T HIV-1–producing cells (B). Lipid classes are standardized to all lipids measured. Cer, ceramide; Chol, cholesterol; -O, ether or odd-numbered fatty acyl residue. Data are presented as mean ± S.D. of three independent experiments, except for ΔNef particles produced in the presence of SERINC5 (n = 2). Note that low-abundant lipid classes are presented in separate graphs on the right. C, relative contribution of SP, GP, and sterols (ST, cholesterol) to the lipid composition of HIV-1–producing cells and OptiPrep-purified HIV-1NL4.3 WT or ΔNef particles produced in the absence or presence of SERINC5.
and antagonism by Nef occur in the absence of overall differences in lipid composition.

**SERINC5 does not alter sphingosine metabolism**

Our previous observation that expression of SERINC5 did not affect the global steady-state lipid composition of HIV particles did not exclude that the restriction factor alters the kinetics of lipid biosynthesis in functionally relevant ways. We therefore assessed next whether expression of SERINC5 alters the metabolism of sphingosine, the main building block of serine-dependent SP synthesis, which begins with the condensation of serine and CoA-activated palmitate, followed by the subsequent generation of sphinganine, ceramide, and key end products such as SM and glucosylceramide (Fig. 4A). To this end, we made use of a functionalized sphingosine (pacSph) containing a photoactivatable diazirine group and a clickable alkyne terminus to enable copper-catalyzed alkyne-azide cycloaddition. In cells, pacSph undergoes metabolism like its natural counterpart (50, 51), leading to the synthesis of complex functionalized sphingolipids. In the presence of sphingosine-1-phosphate lyase, an enzyme involved in degradation of sphingosine, the hydrocarbon backbone of pacSph, which contains the photoactivatable and clickable functionalities, is also fluxed into the glycerol- and phosphoglycerolipid biosynthetic pathway (50, 51) (Fig. 4A). Thus, the kinetics of SP, GP, and glycerolipids (GL) can be monitored at the same time. Cells cultured in the presence of pacSph were lysed after different times of incubation. Cell lysates were subjected to lipid extraction and copper-catalyzed alkyne-azide cycloaddition of a fluorescent dye (Fig. 4B). Lipids were separated by TLC to monitor the kinetics of SP, GP, and GL (Fig. 4C). Quantitative analysis of lipid classes showed that sphingosine metabolism in 293T cells were not affected by the presence of SERINC5.

**SERINC5 restriction is not linked to altered phosphatidylserine exposure on HIV particles**

As an alternative explanation for the effects of SERINC5 on HIV particle infectivity, we considered that the restriction factor may induce a unique exposure profile of phosphatidylserine (PS) on HIV particles. PS exposure is a critical factor for determining HIV particle infectivity, and modifications to the lipid composition of the viral membrane can affect PS exposure. Our results suggest that SERINC5 restriction does not lead to a unique PS exposure profile on HIV particles, as measured by annexin V binding assays (Fig. 3B). These data indicate that SERINC5 restriction is not linked to altered phosphatidylserine exposure on HIV particles.
Lack of lipid modulation in antiviral activity of SERINC5

Figure 4. Analysis of sphingosine metabolism in the absence or presence of SERINC5. A, metabolism of sphingosine (Sph); pacSph fed to cells can either enter the biosynthetic (orange) or degradative (purple) pathway. In SP biosynthesis, ceramide serves as a branching point for the synthesis of phosphosphingolipids such as SM and glycosphingolipids such as glucosylceramide (GlcCer). Breakdown of sphingosine yields shuttles the hydrocarbon backbone via palmitoyl-CoA into biosynthesis of GL and GP. B, pacSph contains a photoactivatable diazirine group and a terminal alkyne moiety. pacSph is metabolized like its endogenous counterpart, entering both the biosynthetic and degradation pathways, giving rise to functionalized cellular lipids. Following lysis at different times of labeling, cells are subjected to a click reaction to couple a fluorescent reporter to alkyne-containing lipids. Following TLC separation, lipids were visualized by fluorescence imaging.

To test this hypothesis, we first sought to quantify surface PS levels on HIV-1 particles and employed flow cytometry, following protocols for the analysis of liposomes of the size of HIV-1 particles (56) or of purified HIV-1 particles (57). As a positive control, liposomes with defined lipid composition and the approximate size of HIV particles (100–150 nm) were used. Liposomes only containing PC or a mixture of PC and PS (50% PS) were undistinguishable by size and granularity and did not display fluorescence when unstained (data not shown). Staining with a PS-specific antibody (anti-PS) (Fig. 5A) or with Mfg8.EGFP, a protein that binds to PS (58, 59) (Fig. 5B), readily detected PS-positive populations in PC/PS liposomes, and, in line with previous results, significantly reduced background binding was observed with PC liposomes (60). Using this setup, purified HIV particles were detectable by FACS and could be identified, e.g., by the incorporation of Vpr.GFP (data not shown). We therefore stained purified HIV-1 WT and ΔNef particles produced in the absence or presence of SERINC5 with Mfg8.EGFP (Fig. 5, C and D). Surprisingly, a robust population of particles produced in the absence of SERINC5 was found to expose PS independently of Nef. The frequency and intensity of this PS positivity, however, were unchanged for virions produced from SERINC5-positive cells (Fig. 5, C and D). Although the percentage of HIV-1 particles detected as PS-positive varied between virions produced and stained on different days (60% for the particle preparations shown in Fig. 5C, ranging from 50–90%), virion preparations generated and analyzed in parallel displayed comparable PS positivity irrespective of expression of Nef or SERINC5. Comparable frequencies of PS-positive HIV-1 particles produced in the absence or presence of SERINC5 and/or Nef were also detected with the anti-PS antibody (Fig. 5E, 10–98% of HIV-1 particles detected as PS-positive). We conclude...
Lack of lipid modulation in antiviral activity of SERINC5
that HIV-1 particles carry a substantial amount of externalized PS independent of SERINC5 expression.

**Competing with PS binding sites on target cells does not affect SERINC5 restriction**

To test whether SERINC5 may introduce qualitative rather than quantitative changes to PS levels exposed on HIV particles, we next tested whether saturation of PS receptors on target cells affects SERINC5 restriction to virion infectivity. To this end, PC-, PE-, or PS-containing liposomes were incubated with target cells to block PS receptors and interfere with PS-dependent virus uptake. As a control, we used infection of Huh7 cells with HCV and scored the expression of the viral NS5A protein as a marker for productive infection by Western blotting. In line with a recent report (61), preincubation of Huh7 cells with PS but not PC or PE liposomes efficiently reduced HCV infection (Fig. 5F). In contrast, parallel treatment of TZM-bl cells had no effect on HIV-1 infection (Fig. 5G). In particular, the strong inhibition of HIV-1ΔNef infectivity by SERINC5 was maintained even in the presence of 100 μM PS receptor-competing PS liposomes. Together, these results illustrate that restriction of HIV-1 infectivity by SERINC5 does not involve targeting of HIV-1 particles to non-productive apoptotic mimicry entry routes.

**Discussion**

Based on the reported ability of SERINC proteins to feed serine into SP biosynthesis pathways, an attractive and often suggested model predicts that its pronounced negative effect on virus infectivity reflects alterations in virion lipid composition (7, 8, 34, 38, 62). The goal of this study was to test this hypothesis and assess whether expression of SERINC5 alters the lipid composition and organization of HIV-1 particles and whether such putative effects contribute to the antiviral activity of SERINC5. Our results do not support these hypotheses because, under experimental conditions where infectivity of HIV-1ΔNef was potently suppressed, expression of SERINC5 during HIV production did neither affect sphingosine metabolism of producer cells nor the overall lipid composition or PS externalization of HIV particles.

Together, these results seem to refute the idea that the restriction of SERINC5 to HIV infectivity is mediated by alterations in HIV lipid composition. Although our quantitative lipidomics analysis covered a comprehensive range of all major lipid classes, these analyses cannot exclude the involvement of rare lipid species we were not able to detect by our mass spectrometry approach. However, it seems unlikely that a serine incorporation function of SERINC5 would be required for such an effect because we did not observe any difference in the abundance of any of the key products of serine-dependent lipid biosynthesis that would also be required for the generation of such still to be determined lipids. Our bulk analysis of whole cell membrane lipids also does not exclude that SERINC5 may have subtle effects on the lipid composition of the plasma membrane, from which HIV particles bud. Such changes, however, should become apparent in virions whose lipid composition was unaffected by SERINC5 in our analysis. We therefore favor the idea that SERINC5 suppresses HIV virion infectivity by alternative mechanisms. In line with a previous report on the effect of Nef on the accessibility of Env in virions to antibody neutralization (63), such effects could include alterations in organization and abundance of Env-containing microdomains at the plasma membrane and in virions. In this scenario, SERINC5 may create a local microenvironment that impairs the fusogenic potential of Env by physical association or indirect mechanisms (38). Such effects of SERINC5 may well be independent of its putative serine incorporator activity. Alternatively, serine incorporation may allow SERINC5 to affect metabolic processes other than lipid biosynthesis that impact HIV particle infectivity.

In addition to the mechanism of antiviral activity of SERINC5, the findings presented here expand our knowledge of the general properties of this restriction factor. The name-giving study by Inuzuka et al. (35) characterized SERINC proteins as transmembrane proteins that have the ability to associate with key enzymes of SP biosynthesis and to incorporate serine into membranes, which suggests that they may facilitate the synthesis of PS and SP. Our comparison of SERINC5-negative 293T cells with 293T cells that overexpress functional levels of SERINC5 did not reveal significant differences in abundance of SP and PS. Serine incorporation by SERINC5 therefore does not seem to contribute to the biosynthesis of these lipids in this experimental system. Similar findings were made recently in a mouse strain in which expression of SERINC1 is abolished by retroviral insertion but did not affect the composition of serine-derived lipids in lymphocytes and macrophages (64). The fact that no significant changes in cellular SP composition were observed upon manipulation of individual SERINC proteins may reflect compensation of the serine incorporator function by other members of the SERINC pro-

**Figure 5. PS surface levels on liposomes and HIV-1 particles and liposome competition for PS binding sites in the context of HIV-1 infection.** A, percentages of PS-positive liposomes detected with PS-specific antibody. PC- and PS/PC-containing liposomes (100 μl of 1 mM liposome stock solution) were incubated with a PS-specific antibody (1:100, 1 h at 4°C) followed by an anti-mouse APC-coupled secondary antibody (1:200, 1 h, 4°C) and analyzed by flow cytometry. Unstained liposomes served as a control. B, percentages of PS-positive liposomes detected with Mfge8.eGFP, PC- and PS-containing liposomes (100 μl of 1 mM liposome stock solution) were incubated with recombinant Mfge8.eGFP (1:100) and analyzed by flow cytometry. Unstained liposomes served as a control. C, percentages of PS-positive HIV-1 particles stained with recombinant Mfge8.eGFP. HIV-1ΔNef WT or ΔNef particles (50 μl with approximately 5 × 10⁸ picounits RT/μl) produced in the absence (control) or presence of SERINC5 (SERINC5) were incubated with Mfge8.eGFP (1:100) and analyzed by flow cytometry. Unstained virus particles served as a control. D, quantification of PS-positive HIV-1 particles as analyzed in C. Percentages of PS-positive particles as determined by the Mfge8.eGFP signal are shown relative to HIV-1 WT particles + control (set to 100%) (n = 3). E, quantification of PS-positive HIV-1 particles analyzed with an anti-PS antibody. Percentages of PS-positive particles (average values from four independent experiments) are shown relative to HIV-1 WT particles + control (set to 100%). F, Western blot analysis of Huh7.5 cells infected with HCV (multiplicity of infection = 10) at 37°C for 8 h in the absence (w/o) or presence of different concentrations (10 and 30 μM) of PC-, PE-, or PS-containing liposomes. Cells were lysed 48 h after infection and subjected to SDS-PAGE, and HCV NS5A was detected via immunostaining. TfR served as a loading control. Shown is one representative of two independent experiments. G, HIV-1 infection of TZM-bl cells in the absence or presence of different concentrations (10 and 30 μM) of PC-, PE-, or PS-containing liposomes. HIV-1 WT or ΔNef (2 × 10⁷ picounits RT/μl) produced in the absence (control) or presence of SERINC5 (SERINC5) was used for the infection. 48 h after infection, cells were lysed, and infection rates were determined via luciferase assay. Infection rates are presented relative to HIV-1 WT + control, which was arbitrarily set to 100%. Shown are means of two independent experiments, each performed in triplicate.
tein family. Cell system–specific differences in the relative contribution of individual SERINC proteins to SP synthesis may also exist. Nevertheless, it needs to be considered that the serine incorporator activity demonstrated by Inuzuka et al. (35) does not primarily feed into SP synthesis or may not even represent the key physiological activity of SERINC proteins.

Together, the results presented here demonstrate that the potent antiviral activity of SERINC5 does not rely on alterations of host cell and virion lipid composition and warrant further investigation into the biological activities of SERINC proteins.

Experimental procedures

Cell lines, reagents, and plasmids

293T cells were cultivated in DMEM with 10% FCS and 1% penicillin-streptomycin (all from Invitrogen). The following antibodies were used: mouse anti-HA.11 (clone 16B12, Biologend), mouse anti-phosphotyrosine (clone 1H6e, sheep anti-HIV–1 capsid (p24) antiserum (kindly provided by Barbara Müller), sheep anti-Nef (arp444, National Institutes of Health AIDS repository), mouse anti-NS5A (9E10, kindly provided by Charles Rice), mouse anti-transferin receptor/CD71 clone H68.4 (Thermo Fisher), and secondary allophycocyanin (APC)-conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories). Human Mfge8.eGFP fusion protein, a fusion protein of full-length human milk fat globule epidermal growth factor 8 (Mfge8), also known also lactadherin, was produced from stably transfected HEK293 cells. Mfge8.eGFP binds to PS with high affinity, but not PE, PI, or PG, and displays reduced affinity to PE, PI, and PG, and displays reduced affinity to

Western blot analysis of virions, virus particle preparations were lysed in 2 × 10^6 SDS sample buffer containing 50 mM tris(2-carboxyethyl)phosphine (0.5  m stock (pH 7.0), Sigma).

Single-cell suspensions of human hepatoma-derived HuH7.5 cells were prepared by trypsinization and washed once with PBS. Cells were resuspended at a concentration of 1 × 10^7 cells/ml in Cytomix (69) containing 2 mM ATP and 5 mM glutathione. 10 μg of in vitro transcribed RNA (70) was mixed with 400 μl of the cell suspension and transfected by electroporation with a Gene Pulser system (Bio-Rad) in a cuvette with a gap width of 0.4 cm (Bio-Rad) at 975 microfarad and 270 V. Cells of two transfections were immediately transferred into medium and seeded into a 15-cm-diameter culture dish. Supernatants were collected 48 h after electroporation and filtered through a 0.45-μm-pore membrane, and virus particles were concentrated by ultrafiltration using a centrifugal filter device (Centricon Plus-70, Millipore). Concentrated culture supernatant was stored at −70 °C. Infectivity titers of virus stocks were determined by limiting dilution assay using HuH7.5 cells as described elsewhere (71).

Western blotting

Cells were lysed in 2 × SDS sample buffer containing 50 mM Tris(2-carboxyethyl)phosphine (0.5  m stock in H2O (pH 7.0), Sigma), lysates were sonicated, and proteins were separated on 12.5% SDS gels and blotted to nitrocellulose membranes. Membranes were blocked in 5% milk in phosphate buffered saline Tween-20 (PBS-T) and probed with the following primary antibodies: mouse anti-HA (1:1000), sheep anti-HIV–1 p24CA antiserum (1:5000), sheep anti–HIV-1 Nef (1:1000), mouse anti–TFR (1:500), and mouse anti-HCV NS5A (1:20000). Secondary antibodies were conjugated to horseradish peroxidase for ECL-based detection.

Quantitative lipid analysis

Cells and viral particles were subjected to acidic Bligh and Dyer lipid extractions (72). Lipid standards were added prior to extractions using a master mix containing phosphatidylcholine (13:0/13:0, 14:0/14:0, 20:0/20:0; 21:0/21:0; Avanti Polar Lipids) and sphingomyelin (d18:1 with N-acylated 15:0, 17:0, 25:0;
Lack of lipid modulation in antiviral activity of SERINC5

Lipid stocks solutions of DOPC, DOPE and DOPS (Avanti Polar Lipids, 10 mg/ml in CHCl₃) were prepared. Lipids were mixed and dried under nitrogen and a vacuum for 1 h. Lipids were solubilized in PBS to obtain a final concentration of 1 mM. Liposomes were prepared by 10 freeze-thaw cycles of warming to 42 °C and freezing in liquid nitrogen (−196 °C) and sized by extrusion through a 50-nm polycarbonate filter using a mini extruder device (Avanti Polar Lipids). Size distributions of liposomes were measured by dynamic light scattering (Wyatt Technology).

Analysis of sphingosine metabolism

3 × 10⁵ 293T cells were seeded in 6-well plates and transfected with 2.5 μg of GFP or SERINC5-GFP expression plasmids for 24 h. For pacSph labeling, medium was removed, and cells were washed with PBS and labeled with DMEM containing 10% delipidated FCS and 2 μM pacSph for 18 h, 60 min, 15 min, or 0 min. Labeling medium was removed, and cells were detached using cell dissociation buffer (Thermo Fisher, 13151014), transferred into 1.5-ml tubes, and pelleted (300 × g, 5 min, 4 °C). Cell pellets were washed three times with PBS and resuspended in 300 μl of PBS. For lipid extractions, 600 μl of MeOH and 150 μl of CHCl₃ were added, and samples were mixed by vortexing. Proteins were pelleted (14,000 × g, 5 min), and supernatants were transferred into 2-ml tubes. Following addition of 300 μl of CHCl₃ and 600 μl of 0.1% acetic acid in H₂O, samples were vortexed and centrifuged (14,000 × g, 5 min). The lower organic phase was transferred into a 1.5-ml tube, and the solvent was evaporated in a SpeedVac at 30 °C. Lipids were redissolved in 7 μl of CHCl₃ and 30 μl of freshly prepared click mixture containing 3 μl of 44.5 mM 3-azido-7-hydroxycoumarin (Jena Bioscience, CLK-FA047-1) in DMSO, acetate, 1:1) in a CAMAG ADC2 system. For enhanced fluorescence of the coumarin derivative, the plates were sprayed with 4% (v/v) Hünig’s base (Sigma-Aldrich, 387649) in hexane. HPTLCS were imaged with the Amersham Biosciences Imager 600 at 460 nm.

Generation of liposomes

Lipids were redissolved in 60 μl of 10 mM ammonium acetate in methanol and analyzed on a QTRAP6500 mass spectrometer (Sciex) with chip-based (HD-D ESI Chip, Advion Biosciences) electro spray infusion and ionization via a Triversa Nanomate (Advion Biosciences) as described previously (43). Redissolved lipid extracts were diluted 1:10 in 96-well plates (Eppendorf Twintec 96, colorless, Sigma, Z651400-25A) prior to measurement. Precursor and neutral loss scanning in positive ion mode was employed to measure glycerophospholipids as described previously (43). The remaining samples were subjected to cholesterol determination as described previously (73). Data evaluation was done using LipidView (ABSciex) and a software developed in-house (ShinyLipids).

Analysis of sphingosine metabolism

3 × 10⁵ 293T cells were seeded in 6-well plates and transfected with 2.5 μg of GFP or SERINC5-GFP expression plasmids for 24 h. For pacSph labeling, medium was removed, and cells were washed with PBS and labeled with DMEM containing 10% delipidated FCS and 2 μM pacSph for 18 h, 60 min, 15 min, or 0 min. Labeling medium was removed, and cells were detached using cell dissociation buffer (Thermo Fisher, 13151014), transferred into 1.5-ml tubes, and pelleted (300 × g, 5 min, 4 °C). Cell pellets were washed three times with PBS and resuspended in 300 μl of PBS. For lipid extractions, 600 μl of MeOH and 150 μl of CHCl₃ were added, and samples were mixed by vortexing. Proteins were pelleted (14,000 × g, 5 min), and supernatants were transferred into 2-ml tubes. Following addition of 300 μl of CHCl₃ and 600 μl of 0.1% acetic acid in H₂O, samples were vortexed and centrifuged (14,000 × g, 5 min). The lower organic phase was transferred into a 1.5-ml tube, and the solvent was evaporated in a SpeedVac at 30 °C. Lipids were redissolved in 7 μl of CHCl₃ and 30 μl of freshly prepared click mixture containing 3 μl of 44.5 mM 3-azido-7-hydroxycoumarin (Jena Bioscience, CLK-FA047-1) in DMSO, acetate, 1:1) in a CAMAG ADC2 system. For enhanced fluorescence of the coumarin derivative, the plates were sprayed with 4% (v/v) Hünig’s base (Sigma-Aldrich, 387649) in hexane. HPTLCS were imaged with the Amersham Biosciences Imager 600 at 460 nm.

Liposome competition experiments

For HCV infections in the presence of liposomes, Huh-7.5 cells were incubated with 10 or 30 μM liposomes or medium as control for 30 min at room temperature and then infected with HCV Jc1 at a multiplicity of infection of 10 in the presence of liposomes (10 or 30 μM) at 37 °C for at least 8 h. 48 h after infection, cell lysates were harvested for detection of HCV NS5A by Western blot analysis using an NS5A-specific monoclonal antibody. Transferrin receptor (TfR) was used as a loading control. For HIV-1 infections in the presence of liposomes, TZM-bl cells were incubated with 10 or 30 μM liposomes or medium as control for 30 min at room temperature and then infected with HIV-1 (2 × 10⁶ picounits RT/μl) for 6 h. 48 h after infection, cells were lysed, and the infectivity of HIV-1 particles was determined by analysis of firefly luciferase activity.

Statistical analysis

Statistical analysis of datasets was carried out using Microsoft Excel and GraphPad Prism. Statistical significance of parametrically datasets was analyzed by unpaired two-tailed Student t test: * , p < 0.05; **, p < 0.01; *** , p < 0.001.

Author contributions—O. T. F. and B. B. designed the study and wrote the manuscript. B. T. and B. G. purified HIV-1 particles. C. L. and B. B. performed experiments for quantitative lipid analysis. B. T. performed and analyzed the experiments shown in Figs. 1–3 and 5. J. K., T. B., M. P., H. G. K., and A. R. provided reagents and expertise. All authors approved the final manuscript.
Lack of lipid modulation in antiviral activity of SERINC5

Acknowledgment—We thank Ina Ambiel for expert technical assistance.

References

1. Altfeld, M., and Gale, M., Jr. (2015) Innate immunity against HIV-1 infection. Nat. Immunol. 16, 554–562
2. Simon, V., Bloch, N., and Landau, N. R. (2015) Innate host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546–553
3. Laguette, N., Brégnard, C., Hue, P., Basbous, J., Yatim, A., Larroque, M., Kirchhoff, F., Constantinnou, A., Sobhian, B., and Benkirane, M. (2014) Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156, 134–145
4. Neil, S. J., Zang, T., and Bieniasz, P. D. (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425–430
5. Van Damme, N., Goff, D., Katsura, C., Jorgenson, R. L., Mitchell, R., Johnson, M. C., Stephens, E. B., and Guatelli, J. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245–252
6. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650
7. Rosa, A., Chande, A., Ziglio, S., De Sanctis, V., Bertorelli, R., Goh, S. L., McCauley, S. M., Noswieski, A., Antonarakis, S. E., Luban, J., Santoni, F. A., and Pizzato, M. (2015) HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526, 212–217
8. Usami, Y., Wu, Y., and Göttlinger, H. G. (2015) SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526, 218–223
9. Deacon, N. J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M., Hooker, D. J., McPhee, D. A., Greenway, A. L., Ellett, A., Chatfield, C., Lawson, V. A., Crowe, S., Maerz, A., Sonza, S., Learmont, J. et al. (1995) Genomic structure of an attenuated quasi-species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988–991
10. Kestler, H. W., 3rd, Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., and Desrosiers, R. C. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651–662
11. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. E., and Park, I. W. (2002) HIV Nef inhibits T cell migration. J. Biol. Chem. 277, 46079–46084
12. Hanardhan, A., Swigt, T., Hill, B., Myers, M. P., and Skowronski, J. (2004) HIV-1 Nef binds the DOC2X-ELMO1 complex to activate Rac and inhibit lymphocyte chemotaxis. PLoS Biol. 2, e6
13. Stolp, B., Imle, A., Coelho, F. M., Hons, M., Gorina, R., Lyck, R., Stein, J. V., and Fackler, O. T. (2012) HIV-1 Nef interferes with T-lymphocyte circulation through confined environments in vivo. Proc. Natl. Acad. Sci. U.S.A. 109, 18541–18546
14. Stolp, B., Reichman-Fried, M., Abraham, L., Hannefeld, F., Ellett, A., Chatfield, C., Lawson, V. A., Crowe, S., Maerz, A., Sonza, S., Learmont, J. et al. (2006) Nef-mediated suppression of T cell activation was lost in a term survivor with nonprogressive HIV-1 infection. J. Virol. 80, 8085–8089
15. Simon, V., Bloch, N., and Landau, N. R. (2015) Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat. Immunol. 16, 546–553
16. Keppler, O. T., and Fackler, O. T. (2014) HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, in Antiretroviral proteins SERINC3 and SERINC5 (2015) Cell Host Microbe 3, 245–252
17. Schröder, A., Chande, A., Ziglio, S., Bertorelli, R., Goh, S. L., McCauley, S. M., Noswieski, A., Antonarakis, S. E., Luban, J., Santoni, F. A., and Pizzato, M. (2015) HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526, 212–217
18. Usami, Y., Wu, Y., and Göttlinger, H. G. (2015) SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526, 218–223
19. Deacon, N. J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M., Hooker, D. J., McPhee, D. A., Greenway, A. L., Ellett, A., Chatfield, C., Lawson, V. A., Crowe, S., Maerz, A., Sonza, S., Learmont, J. et al. (1995) Genomic structure of an attenuated quasi-species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988–991
20. Kestler, H. W., 3rd, Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., and Desrosiers, R. C. (1991) Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651–662
21. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L., and Desro-
